Anti-cardiolipin antibody (aCL)

Anti-cardiolipin antibodies (aCL) are a class of autoantibodies directed against cardiolipin, a phospholipid found in mitochondrial membranes, or more commonly against the plasma protein Beta-2-glycoprotein I (Apolipoprotein H) when it is complexed with anionic phospholipids [2, 15]. These antibodies are a hallmark of Antiphospholipid Syndrome (APS) and are frequently detected in patients with Systemic Lupus Erythematosus (SLE) [3, 16]. Pathologically, aCL contribute to a prothrombotic state by interfering with the coagulation cascade and activating endothelial cells and platelets, leading to clinical manifestations such as recurrent venous or arterial thrombosis and pregnancy complications, including recurrent miscarriages [4, 11]. While aCL are not considered traditional therapeutic targets for small molecule drugs, they serve as critical diagnostic biomarkers and drivers of disease [1, 8]. Clinical management focuses on preventing thrombotic events through long-term anticoagulation with drugs like Warfarin and Heparin, or reducing antibody production using immunosuppressants such as Rituximab [6, 17]. Monitoring aCL titers (IgG, IgM, and IgA) is essential for the diagnosis and risk assessment of patients with autoimmune-mediated hypercoagulability [10, 20]. In some cases, therapies like intravenous immunoglobulin (IVIG) are used to neutralize these antibodies through anti-idiotypic interactions [6].

Other names

ACAAnticardiolipin antibodyaCL antibodyAntiphospholipid antibody

Vitamin K epoxide reductase inhibition, Antithrombin III activation, Cyclooxygenase inhibition, B-cell depletion, Complement C5 inhibition, and Anti-idiotypic neutralization.